DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0175333 A1 Shefer Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0175333 A1 Shefer Et Al US 2003.0175333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0175333 A1 Shefer et al. (43) Pub. Date: Sep. 18, 2003 (54) INVISIBLE PATCH FOR THE CONTROLLED Publication Classification DELIVERY OF COSMETIC, DERMATOLOGICAL AND (51) Int. Cl." .......................... A61K 31/715; A61K 9/70 PHARMACEUTICALACTIVE INGREDIENTS (52) U.S. Cl. .............................................. 424/449; 514/61 ONTO THE SKN (76) Inventors: Adi Shefer, East Brunswick, NJ (US); (57) ABSTRACT Samuel Shefer, East Brunswick, NJ (US) The present invention relates to a patch for controlled topical Correspondence Address: or transdermal delivery of effective levels of cosmetic, Diane Dunn McKay dermatological, and pharmaceutical active ingredients onto Mathews, Collins, Shepherd & McKay, P.A. the skin, hair follicles, and Sebaceous glands, with minimal Suite 306 discomfort and ease of use. The patch can be transparent or 100 Thanet Circle clear and comprises a rate-controlling matrix layer. The matrix layer comprises water-Sensitive, bioadhesive, film Princeton, NJ 08540 (US) forming polymers, a water Soluble oligomer, and a Surfac (21) Appl. No.: 10/376,736 tant. The cosmetic, dermatological, and pharmaceutical active ingredients are Soluble or dispersed in the matrix. The (22) Filed: Feb. 28, 2003 patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are Sufficient to main Related U.S. Application Data tain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily (63) Continuation-in-part of application No. 10/091,935, removed without causing skin irritation or leaving adhesive filed on Mar. 6, 2002. residue on the skin. US 2003/0175333 A1 Sep. 18, 2003 INVISIBLE PATCH FOR THE CONTROLLED 0008 U.S. Pat. No. 6,280,764 discloses a patch for DELIVERY OF COSMETIC, DERMATOLOGICAL, topical application of an anti-acne formulation has in various AND PHARMACEUTICALACTIVE INGREDIENTS embodiments a backing film, a release layer and at least one ONTO THE SKN adhesive polymeric matrix layer located between the back 0001. This application is a continuation in part of U.S. ing film and the release layer. The anti-acne formulation is application Ser. No. 10/091,935, filed Mar. 6, 2002, entitled uniformly distributed throughout one or more polymeric “A Patch for Controlled Delivery of Cosmetic, Dermato matrix layers and has an anti-acne effective amount of at logical, and Pharmaceutical Active Ingredients into the least two agents Selected from the group of an anti-micro Skin,” the contents of which are each incorporated by bial, an antiseptic, an anti-irritant, a keratolytic agent, a reference into this application. hormone, a hormone agonist and a hormone antagonist. BACKGROUND OF THE INVENTION 0009 U.S. Pat. No. 6,296,869 discloses a dermal patch which includes a substrate formed of a hydrophobic and 0002) 1. Field of the Invention hydrophilic fiber mixture, and a hydrogel adhesive deposited 0003. The present invention relates to an invisible patch onto the Substrate. The adhesive contains an alpha or beta for the controlled delivery of cosmetic, dermatological, and hydroxy acid. The patch is applied to skin for treating the pharmaceutical active ingredients onto the skin which is Signs of aging, especially around areas of the eye. formed of a Single matrix layer. The patch is applied onto the 0010 U.S. Pat. No. 6,280,765 discloses patch comprising skin by Wetting or moistening the target area. Upon appli a hydrophobic polymer layer bound to a Support layer and cation onto the Skin Surface, the patch dissolves or disinte containing: a) first particles of at least one water-soluble grates and provides a Substantive therapeutic layer to the active compound, b) second particles of oil, c) at least one treatment Site over an extended period of time. liposoluble active compound, d) third particles of a water 0004 2. Description of the Related Art absorbing agent all of which are dispersed homogeneously 0005 The localized treatment of body tissues, diseases, in the polymer layer. This patch allows the packaging and and wounds requires that the particular active ingredient be controlled administration of an assembly of skin-nourishing maintained at the Site of treatment for an effective period of and/or skin-repairing Substances of different nature, and also time. Transdermal patches for the administration of active has excellent adhesive power on the skin. ingredients onto the skin have become very popular in recent 0011 U.S. Pat. No. 5,232,702 describes a patch structure years. These patches adhere to the targeted area and the consisting of an occlusive Support layer and a polymer layer active ingredient is continually absorbed through the skin bound to the Support layer. The polymer layer is formed of into the bloodstream for systemic distribution. a matrix of a Silicone polymer including, in the dispersed 0006 The term “transdermal” as used herein, means State, fatty Substances and hydrophilic active compounds. transdermal or percutaneous administration, i.e. application This form of patch is more particularly suitable for deliv of the skin treating composition directly to the skin to be ering water-Soluble active compounds of lipophilic nature. treated. Hence the terms “skin,”“derma,”“epidermis,” and 0012 U.S. Pat. No. 5,976,565 discloses a patch for the like Shall also be used interchangeably unless Specifi topical application of an anti-acne formulation has in various cally Stated otherwise. embodiments a backing film, a release layer and at least one 0007 Transdermal patches, which permit the controlled adhesive polymeric matrix layer located between the back release of the active ingredients onto the skin, are known ing film and the release layer. The anti-acne formulation is from the literature. Two types of patches for skin applica uniformly distributed throughout one or more polymeric tions are described in the literature. The first type of patches matrix layers and has an anti-acne effective amount of at has a multilayer Structure, where the active ingredients are least two agents Selected from the group consisting of an dissolved or dispersed in the various layers. The Second type anti-microbial, an antiseptic, an anti-irritant, a keratolytic of patch is a pressure-Sensitive adhesive patch, where the agent, a hormone, a hormone agonist and a hormone antago active is dissolved or dispersed in the patch adhesive layer. nist. Multilayer patches normally have a structure comprising Several Successive layers in the following order: a first 0013 U.S. Pat. No. 5,100,672 discloses a pressure sen Support layer, which is typically occlusive, Such as, com Sitive adhesive transdermal patch having a composite adhe posed of a material impermeable to the active compound, So sive layer reinforced with a web layer. Cosmetically bioac as to prevent the evaporation thereof and facilitate transder tive Substances used in the patch include water Soluble mal migration; a Second storage layer fastened to the Support Vitamins Such as Vitamin C, and lipoSoluble Vitamins A and layer and containing the active compound and capable of E or their derivatives. placement directly in contact with the skin; a layer of an 0014 U.S. Pat. No. 6,180,133 discloses an anti-wrinkle adhesive material applied to the Surface of the Storage layer skin treating composition comprises a pressure Sensitive and permeable to the active compound to facilitate attach matrix patch having dissolved in the adhesive a mixture of ment of the patch to the skin; and a detachable protective antioxidants in the form of a Vitamins C ester and Vitamin E. layer which hermetically covers the Storage layer So as to Also preferably dissolved in the adhesive are glycerine and protect it from any external contamination during Storage a polydiorganosiloxane adhesion-adjusting agent. Option prior to use of the patch. In the preSSure Sensitive adhesive ally dissolved in the adhesive is also one or more members patches, the bioactive Substances are mixed with and for Selected from the group consisting of moisturizing agents, mulated into a pressure Sensitive adhesive matrix which may skin collagen Synthesis promoting agents and exfoliating be Subsequently coated as a single pressure Sensitive adhe agents. When applied to a wrinkled skin area the composi Sive layer. tion acts to diminish fine wrinkles and improves the overall US 2003/0175333 A1 Sep. 18, 2003 thickness, elasticity, firmness and Smoothness of the skin. DETAILED DESCRIPTION OF THE The modified adhesive properties of the patch are sufficient INVENTION to maintain the patch in place on the skin for the recom 0019. The present invention relates to a novel patch to mended treatment period while allowing the patch to be deliver cosmetic, dermatological, and pharmaceutical active readily removed without causing skin irritation or leaving ingredients onto the Skin, hair follicles, and Sebaceous adhesive residue on the Skin. glands. The patch can be translucent or invisible. Upon 0015 EP-A-0346211 describes the use of a copolymer application and adherence of the patch to the Surface of skin, of 2-ethyl-hexyl acrylate and N-vinyl-2-pyrrolidone without the cosmetic, dermatological, and pharmaceutical active ingredients, diffuse, or penetrate the Surrounding tissues, and absorption promoters. EP-A-0 272918 describes the use of provide effective delivery to the treatment site. The patch of a macroporous foam in which active ingredient is present in the present invention offers the advantages of an effective immobilized form. EP-A-0 409 383 describes an estrogen residence time with minimal discomfort and ease of use, and containing patch in the concentration range from 0.01 to 1% is an appropriate vehicle for local as well as Systemic of an estrogen in combination with a water-insoluble vinyl delivery of active ingredients. pyrrollidone for retarded release of the active ingredient to the skin.
Load more

Recommended publications
  • Fast Facts Core Curriculum Wounds and Oral Care
    Fast Facts Core Curriculum Wounds and Oral Care #37 Pruritus . .2-3 #40 Pressure Ulcer Management: Staging and Prevention . 4-5 #41 Pressure Ulcers: Debridement and Dressings . .6-7 #46 Malignant Wounds . 8-9 #121 Oral Mucositis: Diagnosis and Assessment . .10-11 #130 Oral Mucositis: Prevention and Treatment . 12-13 #147 Oropharyngeal Candidiasis . 14-15 #182 Xerostomia . 16-17 #218 Managing Wound Odor . 18-20 #249 Topical Nonsteroidal Anti-Inflammatory Drugs . 21-22 #250 Tracheostomy Care . .23-25 #281 Care of the Post-Laryngectomy Stoma . .26-28 1 #327 Topical Treatments for Acute and Chronic Wound Pain . .29-31 2 ! FAST FACTS AND CONCEPTS #37 PRURITUS Charles von Gunten MD and Frank Ferris MD Background Pruritus (itching) is a common and often distressing symptom near the end of life. The itch sensation may arise from stimulation of the skin itch receptor via unmyelinated C fibers, or itch may arise as a central phenomenon without skin involvement (e.g. opioid induced pruritus). Although histamine causes pruritus, many patients with pruritis show no signs of histamine release. Besides histamine, serotonin, prostaglandins, kinins, proteases and physical stimuli have all been implicated as mediators of pruritus. Common Causes • Dermatological (dryness, wetness, irritation, eczema, psoriasis) • Metabolic (hepatic failure, renal failure, hypothyroidism) • Hematologic (iron deficiency, polycythemia, thrombocytosis, leukemia, lymphoma) • Drugs (opioids, aspirin, drug reactions) • Infectious (scabies, lice, candida) • Allergy (urticaria, contact dermatitis, drug reactions) • Psychogenic Management Management of pruritus involves eliminating the cause when possible. Symptomatic strategies include: • Moisturizers: Dryness (xerosis) is very common and may exacerbate other causes. The mainstay of treatment is skin hydration.
    [Show full text]
  • Pharmaceutical Compoundingand Dispensing, Second
    Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • Pharmacology for Dentistry
    This page intentionally left blank Copyright © 2007, New Age International (P) Ltd., Publishers Published by New Age International (P) Ltd., Publishers All rights reserved. No part of this ebook may be reproduced in any form, by photostat, microfilm, xerography, or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of the publisher. All inquiries should be emailed to [email protected] ISBN (13) : 978-81-224-2556-7 PUBLISHING FOR ONE WORLD NEW AGE INTERNATIONAL (P) LIMITED, PUBLISHERS 4835/24, Ansari Road, Daryaganj, New Delhi - 110002 Visit us at www.newagepublishers.com This page intentionally left blank PrefacePreface Pharmacology has undergone major intellectual changes in the recent years and has become increasingly important to all medical, dental and other health professionals. The graduate students of dentistry may have to handle medical emergency during various dental procedures on the dental chair. Besides this, dentists have to look into various drug associated interactions. The broad goal of teaching pharmacology to undergraduate students is to inculcate rational and scientific basis of therapeutics keeping in view the dental curriculum and profession. A sincere attempt has been made to present a complete text for undergraduate students of dentistry as per the new syllabus requirement (Dental Council of India, BDS course regulation, 2006). The book is divided into thirteen sections, initial sections cover the general and autonomic pharmacology, followed by other sections of drug acting on different body systems. A detailed section is devoted only to dental pharmacology which covers all agents used in pharmacotherapy of dental conditions.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,858,570 B2 Hare (45) Date of Patent: Dec
    US00785857OB2 (12) United States Patent (10) Patent No.: US 7,858,570 B2 Hare (45) Date of Patent: Dec. 28, 2010 (54) COMPOSITIONS AND METHODS FOR 5,607,980 A 3, 1997 McAtee et al. REMOVINGURUSHOLAND TREATING 5,643,572 A 7/1997 Byers THE RESULTING SKIN CONDITION 5,686,074 A * 1 1/1997 Stewart ...................... 424,736 5,753,245 A 5/1998 Fowler et al. 76 O O 5,767,109 A * 6/1998 Sanchez et al. ............... 514,58 (76) Inventor: year tariusSon La., 5,811,111 A 9/1998 McAtee et al. s 5,859,066 A 1/1999 Rosen 5.990,065. A 11, 1999 V tal. (*) Notice: Subject to any disclaimer, the term of this 6,022,565 A 2, 2000 XE e patent is extended or adjusted under 35 6,110,475 A 8, 2000 Toma et al. U.S.C. 154(b) by 654 days. 6,113,929 A 9, 2000 Karl 6,423,746 B1* 7/2002 Yarbrough et al. .......... 514,561 (21) Appl. No.: 11/930,098 6,667,026 B1 12/2003 Goldman et al. 7,001,622 B1 2/2006 Berndt (22) Filed: Oct. 31, 2007 7,008,963 B2 3/2006 Yarbrough 7,025,972 B2 4/2006 Beall (65) Prior Publication Data 7,144,173 B2 12/2006 Policicchio et al. 7,198.806 B2 4/2007 Berndt US 2008/O1 O7742 A1 May 8, 2008 7.351,474 B2 * 4/2008 Etzrodt et al. ............... 428/407 Related U.S. Application Data * cited by examiner (62) Division of application No.
    [Show full text]
  • WO 2018/005695 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2018/005695 A l 0 4 January 2018 (04.01.2018) W ! P O PCT (51) International Patent Classification: (72) Inventors: BASTA, Steven; 590 Berkeley Avenue, Menlo A61K 31/4035 (2006.01) A61P 17/04 (2006.01) Park, CA 94025 (US). JOING, Mark; 936 Clara Drive, Pa A61K 45/06 (2006.01) lo Alto, CA 94303 (US). ZHANG, Xiaoming; 1089 Rem- sen Court, Sunnyvale, CA 94087 (US). KWON, Paul; 3349 (21) International Application Number: Deer Hollow Dr, Danville, CA 94506 (US). PCT/US20 17/039829 (74) Agent: SILVERMAN, Lisa, N.; Morrison & Foerster LLP, (22) International Filing Date: 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). 28 June 2017 (28.06.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/356,280 29 June 2016 (29.06.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/356,291 29 June 2016 (29.06.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/356,301 29 June 2016 (29.06.2016) us MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/356,294 29 June 2016 (29.06.2016) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/356,286 29 June 2016 (29.06.2016) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, 62/356,271 29 June 2016 (29.06.2016) us TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Topical Agents for the Management of Musculoskeletal Pain Steven P
    342 Journal of Pain and Symptom Management Vol. 33 No. 3 March 2007 Special Article Topical Agents for the Management of Musculoskeletal Pain Steven P. Stanos, DO Chronic Pain Care Center, Rehabilitation Institute of Chicago, and Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Abstract The recent recognition of the magnitude of cardiovascular risk of both nonselective nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors, in addition to the persistent concerns about the use of opioids, has brought increased attention to nonsystemic, topical analgesics. These agents have a favorable safety profile and there is increasing evidence indicating their efficacy for a variety of pain disorders. The use of topical analgesics in the treatment of the most prevalent musculoskeletal pain syndromes is described, with a focus on mechanisms for drug delivery and clinical trials data. J Pain Symptom Manage 2007;33:342e355. Ó 2007 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. Key Words Counterirritants, local anesthetics, musculoskeletal pain, topical analgesics Introduction may provide a safe and effective therapeutic approach for some musculoskeletal pains. Musculoskeletal pain encompasses a wide spectrum of disorders from simple ligamen- tous injuries (e.g., ankle sprains) to intra- articular disorders (e.g., osteoarthritis and rheumatoid arthritis), muscle pain syndromes Epidemiology (e.g., myofascial pain and fibromyalgia), and Low back pain (LBP) and osteoarthritis are various spine-related neck and low back condi- the most common musculoskeletal disorders. tions (e.g., disc degeneration, disc herniation, LBP creates a significant burden on society facet arthropathies, and spondylosis).
    [Show full text]
  • Managing Symptoms in the Pharmacy in the Pharmacy
    Managing Symptoms Managing Symptoms in the Pharmacy in the Pharmacy • Are your exams coming up? • Are you drowning in textbooks and lecture notes and wondering where to begin? Take the FASTtrack route to successful revision for your examinations. FASTtrack provides the ultimate lecture notes and is a must-have for all pharmacy undergraduate students wanting to revise and test themselves for forthcoming exams. Managing Symptoms in the Pharmacy focuses on what pharmacy students really need to know in order to pass exams, providing concise, bulleted information, key points, tips and an all-important self-assessment section which includes MCQs, case studies, sample essay questions and worked examples. Addressing all common ailments, organised by system in alphabetical order, this FASTtrack book provides all the essential information needed for managing symptoms presented in the pharmacy. Managing Visit the FASTTrack website www.fasttrackpharmacy.com for extra MCQs, sample online content and much more. Symptoms in www.pharmpress.com the Pharmacy Nathan Alan Nathan Managing Symptoms in the Pharmacy Managing Symptoms in the Pharmacy Alan Nathan Freelance pharmacy writer and consultant London, UK Pharmaceutical Press London • Chicago Published by the Pharmaceutical Press An imprint of RPS Publishing 1 Lambeth High Street, London SE1 7JN, UK 100 South Atkinson Road, Suite 200, Grayslake, IL 60030-7820, USA © Pharmaceutical Press 2008 is a trade mark of RPS Publishing RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain First published 2008 Design and layout by Designers Collective, London Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 727 5 All rights reserved.
    [Show full text]
  • 2004 Doping Control Annual Report
    RAPPORT ANNUEL SUR LES SUBSTANCES PROHIBEES ANNUAL REPORT ON PROHIBITED SUBSTANCES 2 0 0 4 by Dr Helena Nicolas-Frey, Fédération Nationale des Courses Françaises [email protected] - 1 - The Annual Report on Doping Control for the year 2004 is based on the answers received from 48 countries. As usual some countries have provided answers corresponding to the 2004/2005 racing season. The information received is presented in tables and is commented in seven chapters, according to the plan adopted in previous years. 1. RACING SAMPLES 359 938 horses (among them approximately 115 000 in USA) were sampled, including in pre-race testing, for a total of 177 440 flat and jumping races. The average number of horses tested by race amounted to 2.03. Concerning this result, it should be noted that, in some countries, this control is currently limited to the most important races of their annual racing program. In other countries, tests are systematically performed before and after each race on one or more horses per race. The analyses of both urine and blood samples has led to 1 053 positive results, i.e. 0.29% of the total tests carried out (0.17% in 2003). The majority of the prohibited substances detected were found in urine samples. In blood samples, in addition to carbon dioxide (TC02), the substances detected were non steroidal anti-inflammatory drugs, caffeine and its metabolites. 25 positive cases contained two different prohibited substances and 2 cases, three substances that were, three non steroidal anti-inflammatory drugs. 2. TRAINING SAMPLES Control in training in 2004 was carried out in 14 countries (Australia, France, Germany, Great Britain, Greece, Hong Kong, India, Ireland, Italy, Japan, Korea, Macau, Mauritius, South Africa).
    [Show full text]
  • OTC Ingredient List Alphabetical by Ingredient 022709
    OTC Ingredient List (Alphabetical) August 2008 Active Ingredient Monograph Sub-category Panel Pending Final FR Citation 2-ethylhexyl-4-phenylbenzophenone-2-carboxylic acid sunscreen II IISE acetaminophen internal analgesic I I acetaminophen menstrual/diuretic analgesic I acetaminophen nighttime sleep aid II IISE 54 FR 6826 overindulgence in acetaminophen alcohol/food hangover reliever I acetanilide internal analgesic II IIS acetic acid otic 310.545(a)(15)(i) acetic acid wart remover III IIISE [55 FR 33254] acetic acid, glacial corn/callus remover II IIISE [55 FR 33254] acetic acid, glacial wart remover III IIISE [55 FR 33254] acetone skin protectant astringent 310.545(a)(18)(ii) acidulated phosphate fluoride anticaries I 355.10(a)(3)(i) acidulated phosphate fluoride anticaries I 355.10(a)(3)(ii) agar laxative bulk laxative III 310.545(a)(12)(i) alcloxa acne II II 310.545(a)(1) alcloxa anorectal keratolytic I(e) I(e) 346.20(a) alcloxa antifungal III III 310.545(a)(22)(ii) alcohol digestive aid 310.545(a)(8)(ii) alcohol external analgesic insect bite/sting 310.545(a)(10)(vi) alcohol external analgesic poison ivy/oak/sumac 310.545(a)(10)(vii) alcohol menstrual/diuretic 310.545(a)(24)(i) alcohol mercury I alcohol oral health care III IIISE alcohol skin protectant astringent 310.545(a)(18)(ii) alcohol skin protectant insect bites/stings 310.545(a)(18)(v)(A) alcohol skin protectant poison ivy/oak/sumac 310.545(a)(18)(vi)(A) alcohol skin protectant IISE alcohol weight control II 310.545(a)(20) alcohol, ethoxylated alkyl external analgesic insect
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,474,741 B2 Zhang Et Al
    USOO9474741 B2 (12) United States Patent (10) Patent No.: US 9,474,741 B2 Zhang et al. (45) Date of Patent: *Oct. 25, 2016 (54) USE OF NK-1 RECEPTOR ANTAGONISTS IN 5,521, 183 A 5/1996 Woodward et al. PRURTUS 5,629,327 A 5, 1997 D’Amato 5,679,360 A 10, 1997 De Lacharriere et al. 5,869,521 A 2f1999 Farrar et al. (71) Applicant: MENLO THERAPEUTICS INC., 5,981,513 A 1 1/1999 Kruse et al. Menlo Park, CA (US) 6,054,445 A 4/2000 Zhang et al. 6,221,880 B1 4, 2001 Shih (72) Inventors: Xiaoming Zhang, Sunnyvale, CA (US); 6476,063 B2 11/2002 Zhang et al. Edward F. Schnipper, Redwood City, 6,743,793 B2 6/2004 Torisu et al. 7,153,852 B2 12/2006 Torisu et al. CA (US); Andrew J. Perlman, 7,217,731 B2 5/2007 Bunda et al. Stanford, CA (US); James W. Larrick, 7,345,083 B2 3/2008 Bunda et al. Sunnyvale, CA (US) 7,435,745 B2 10/2008 D'Amato 7,511,072 B2 3/2009 Man et al. (73) Assignee: MENLO THERAPEUTICS INC., 7,544,815 B2 6/2009 Kuethe et al. Menlo Park, CA (US) 7,645,790 B2 1/2010 Bunda et al. 7,683,068 B2 3/2010 Jiang et al. 7,732.479 B2 6, 2010 Gazit et al. (*) Notice: Subject to any disclaimer, the term of this 7,740,959 B2 6/2010 Yagi patent is extended or adjusted under 35 7,893,091 B2 2/2011 Gottesdiener et al.
    [Show full text]
  • ( 12 ) United States Patent
    THAT US009737507B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 737 ,507 B2 Zhang et al . (45 ) Date of Patent: * Aug. 22 , 2017 ( 54 ) USE OF NK - 1 RECEPTOR ANTAGONIST ( 56 ) References Cited SERLOPITANT IN PRURITUS U . S . PATENT DOCUMENTS (71 ) Applicant : MENLO THERAPEUTICS INC ., 5 ,077 , 142 A 12 / 1991 Sakon et al . Menlo Park , CA (US ) 5 , 334 ,606 A 8 / 1994 MacLeod 5 ,521 , 183 A 5 / 1996 Woodward et al. (72 ) Inventors: Xiaoming Zhang , Sunnyvale , CA (US ) ; 5 ,629 , 327 A 5 / 1997 D ' Amato 5 ,679 , 360 A 10 / 1997 De Lacharriere et al . Edward F . Schnipper , Redwood City , 5 , 869 ,521 A 2 / 1999 Farrar et al. CA (US ) ; Andrew J . Perlman , 5 , 981, 513 A 11 / 1999 Kruse et al . Stanford , CA (US ) ; James W . Larrick , 6 ,054 , 445 A 4 / 2000 Zhang et al. Sunnyvale , CA (US ) 6 ,221 , 880 B1 4 / 2001 Shih 6 , 476 , 063 B2 11/ 2002 Zhang et al. 6 , 743 , 793 B2 6 / 2004 Torisu et al . ( 73 ) Assignee : MENLO THERAPEUTICS INC ., 7 ,153 , 852 B2 12 /2006 Torisu et al. Menlo Park , CA (US ) 7 , 217 , 731 B2 5 /2007 Bunda et al . 7 , 345 , 083 B2 3 / 2008 Bunda et al . 7 , 435 , 745 B2 10 / 2008 D ' Amato ( * ) Notice: Subject to any disclaimer, the term of this 7 , 511 , 072 B2 3 / 2009 Man et al . patent is extended or adjusted under 35 7 , 544 , 815 B2 6 / 2009 Kuethe et al. U . S .C . 154 ( b ) by 0 days . 7 , 645 , 790 B2 1 /2010 Bunda et al.
    [Show full text]
  • ( 12 ) United States Patent
    US010278953B2 (12 ) United States Patent (10 ) Patent No. : US 10 ,278 , 953 B2 Zhang et al . (45 ) Date of Patent : *May 7 , 2019 ( 54 ) USE OF NK - 1 RECEPTOR ANTAGONIST USPC .. .. .. 548 /400 SERLOPITANT IN PRURITUS See application file for complete search history . (71 ) Applicant : Menlo Therapeutics Inc ., Redwood City , CA (US ) ( 56 ) References Cited ( 72 ) Inventors : Xiaoming Zhang , Sunnyvale , CA (US ) ; U . S . PATENT DOCUMENTS Edward F . Schnipper , Redwood City , 5 ,077 , 142 A 12 / 1991 Sakon et al. CA (US ) ; Andrew J . Perlman , 5 , 334 ,606 A 8 / 1994 MacLeod Stanford , CA (US ) ; James W . Larrick , 5 , 521 , 183 A 5 / 1996 Woodward et al . Sunnyvale , CA (US ) 5 ,629 , 327 A 5 / 1997 D ' Amato 5 ,679 , 360 A 10 / 1997 De Lacharriere et al. 5 , 869 ,521 A 2 / 1999 Farrar et al . ( 73 ) Assignee : Menlo Therapeutics Inc ., Redwood , 5 , 981, 513 A 11/ 1999 Kruse et al . CA (US ) 6 ,054 ,445 A 4 / 2000 Zhang et al . 6 , 221 , 880 B1 4 / 2001 Shih ( * ) Notice: Subject to any disclaimer , the term of this 6 ,476 , 063 B2 11/ 2002 Zhang et al. patent is extended or adjusted under 35 6 , 476 , 083 B1 11/ 2002 Okuru et al . U . S . C . 154 (b ) by 0 days . 6 ,743 ,793 B2 6 / 2004 Torisu et al . 7 , 153 , 852 B2 12 /2006 Torisu et al . This patent is subject to a terminal dis 7 ,217 , 731 B2 5 / 2007 Bunda et al. 7 , 345 , 083 B2 3 / 2008 Bunda et al . claimer . 7 , 435 , 745 B2 10 /2008 D ' Amato 7 ,511 ,072 B2 3 / 2009 Man et al .
    [Show full text]